Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?

Elizabeth Cathcart-Rake, Deanne Smith, David Zahrieh, Aminah Jatoi, Ping Yang, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the frequency of nasal symptoms termed nasal vestibulitis, including nasal dryness, crusting, bleeding, and pain, among patients receiving systemic, antineoplastic therapy. Methods: Patients undergoing systemic antineoplastic therapy were interviewed regarding the presence of nasal symptoms. In an explorative approach, Fisher’s exact tests were used to identify groups in which frequencies of nasal symptoms were higher than the comparator arm. To account for potential confounding factors, including demographic variables and concurrent therapies, logistic regression analyses were performed, and estimated proportions with their standard errors (SEs) and odds ratios (ORs) were reported. Results: Forty-one percent of the 100 surveyed patients had nasal symptoms, including dryness, pain, bleeding, and scabbing. Higher frequencies were reported among those who had received taxanes (71%) and VEGF-related therapies (78%). For the patients who had received taxanes, after controlling for other factors, the odds of experiencing nasal symptoms were 4.86 times higher than those for patients who did not receive taxanes (90% CI 2.01, 11.76). For patients who received VEGF-related therapies, after controlling for other factors and exposure to taxanes, the odds of experiencing nasal symptoms were 7.38 (90% CI 1.68, 32.51) times higher than those for patients who did not. Sixty-one percent of patients with symptoms said they reported them to their provider, but only 41% of chart notes contained documentation of such; 49% of patients reported treating their symptoms. Conclusions: Nasal vestibulitis is common among patients receiving taxane- and VEGF-related therapies; these symptoms are infrequently recorded or treated by healthcare providers.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - May 24 2018

Fingerprint

Nose
Taxoids
Neoplasms
Vascular Endothelial Growth Factor A
Therapeutics
Antineoplastic Agents
Hemorrhage
Pain
Documentation
Health Personnel
Logistic Models
Odds Ratio
Regression Analysis
Demography

Keywords

  • Chemotherapy toxicity
  • Nasal symptoms
  • Taxane side effects

ASJC Scopus subject areas

  • Oncology

Cite this

@article{8bdf220810674326ab449da943ab6d3e,
title = "Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment?",
abstract = "Purpose: To evaluate the frequency of nasal symptoms termed nasal vestibulitis, including nasal dryness, crusting, bleeding, and pain, among patients receiving systemic, antineoplastic therapy. Methods: Patients undergoing systemic antineoplastic therapy were interviewed regarding the presence of nasal symptoms. In an explorative approach, Fisher’s exact tests were used to identify groups in which frequencies of nasal symptoms were higher than the comparator arm. To account for potential confounding factors, including demographic variables and concurrent therapies, logistic regression analyses were performed, and estimated proportions with their standard errors (SEs) and odds ratios (ORs) were reported. Results: Forty-one percent of the 100 surveyed patients had nasal symptoms, including dryness, pain, bleeding, and scabbing. Higher frequencies were reported among those who had received taxanes (71{\%}) and VEGF-related therapies (78{\%}). For the patients who had received taxanes, after controlling for other factors, the odds of experiencing nasal symptoms were 4.86 times higher than those for patients who did not receive taxanes (90{\%} CI 2.01, 11.76). For patients who received VEGF-related therapies, after controlling for other factors and exposure to taxanes, the odds of experiencing nasal symptoms were 7.38 (90{\%} CI 1.68, 32.51) times higher than those for patients who did not. Sixty-one percent of patients with symptoms said they reported them to their provider, but only 41{\%} of chart notes contained documentation of such; 49{\%} of patients reported treating their symptoms. Conclusions: Nasal vestibulitis is common among patients receiving taxane- and VEGF-related therapies; these symptoms are infrequently recorded or treated by healthcare providers.",
keywords = "Chemotherapy toxicity, Nasal symptoms, Taxane side effects",
author = "Elizabeth Cathcart-Rake and Deanne Smith and David Zahrieh and Aminah Jatoi and Ping Yang and Loprinzi, {Charles Lawrence}",
year = "2018",
month = "5",
day = "24",
doi = "10.1007/s00520-018-4261-7",
language = "English (US)",
pages = "1--6",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Nasal vestibulitis

T2 - Supportive Care in Cancer

AU - Cathcart-Rake, Elizabeth

AU - Smith, Deanne

AU - Zahrieh, David

AU - Jatoi, Aminah

AU - Yang, Ping

AU - Loprinzi, Charles Lawrence

PY - 2018/5/24

Y1 - 2018/5/24

N2 - Purpose: To evaluate the frequency of nasal symptoms termed nasal vestibulitis, including nasal dryness, crusting, bleeding, and pain, among patients receiving systemic, antineoplastic therapy. Methods: Patients undergoing systemic antineoplastic therapy were interviewed regarding the presence of nasal symptoms. In an explorative approach, Fisher’s exact tests were used to identify groups in which frequencies of nasal symptoms were higher than the comparator arm. To account for potential confounding factors, including demographic variables and concurrent therapies, logistic regression analyses were performed, and estimated proportions with their standard errors (SEs) and odds ratios (ORs) were reported. Results: Forty-one percent of the 100 surveyed patients had nasal symptoms, including dryness, pain, bleeding, and scabbing. Higher frequencies were reported among those who had received taxanes (71%) and VEGF-related therapies (78%). For the patients who had received taxanes, after controlling for other factors, the odds of experiencing nasal symptoms were 4.86 times higher than those for patients who did not receive taxanes (90% CI 2.01, 11.76). For patients who received VEGF-related therapies, after controlling for other factors and exposure to taxanes, the odds of experiencing nasal symptoms were 7.38 (90% CI 1.68, 32.51) times higher than those for patients who did not. Sixty-one percent of patients with symptoms said they reported them to their provider, but only 41% of chart notes contained documentation of such; 49% of patients reported treating their symptoms. Conclusions: Nasal vestibulitis is common among patients receiving taxane- and VEGF-related therapies; these symptoms are infrequently recorded or treated by healthcare providers.

AB - Purpose: To evaluate the frequency of nasal symptoms termed nasal vestibulitis, including nasal dryness, crusting, bleeding, and pain, among patients receiving systemic, antineoplastic therapy. Methods: Patients undergoing systemic antineoplastic therapy were interviewed regarding the presence of nasal symptoms. In an explorative approach, Fisher’s exact tests were used to identify groups in which frequencies of nasal symptoms were higher than the comparator arm. To account for potential confounding factors, including demographic variables and concurrent therapies, logistic regression analyses were performed, and estimated proportions with their standard errors (SEs) and odds ratios (ORs) were reported. Results: Forty-one percent of the 100 surveyed patients had nasal symptoms, including dryness, pain, bleeding, and scabbing. Higher frequencies were reported among those who had received taxanes (71%) and VEGF-related therapies (78%). For the patients who had received taxanes, after controlling for other factors, the odds of experiencing nasal symptoms were 4.86 times higher than those for patients who did not receive taxanes (90% CI 2.01, 11.76). For patients who received VEGF-related therapies, after controlling for other factors and exposure to taxanes, the odds of experiencing nasal symptoms were 7.38 (90% CI 1.68, 32.51) times higher than those for patients who did not. Sixty-one percent of patients with symptoms said they reported them to their provider, but only 41% of chart notes contained documentation of such; 49% of patients reported treating their symptoms. Conclusions: Nasal vestibulitis is common among patients receiving taxane- and VEGF-related therapies; these symptoms are infrequently recorded or treated by healthcare providers.

KW - Chemotherapy toxicity

KW - Nasal symptoms

KW - Taxane side effects

UR - http://www.scopus.com/inward/record.url?scp=85047354287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047354287&partnerID=8YFLogxK

U2 - 10.1007/s00520-018-4261-7

DO - 10.1007/s00520-018-4261-7

M3 - Article

SP - 1

EP - 6

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -